Company Oncotrials Srl with Fiscal Code 16822091
recorded a turnover of 2024 of
12.379,
with a net profit of
32
and having an average number of employees of
1.
The company operates in the field of Cercetare-dezvoltare în ştiinţe naturale şi inginerie having the NACE code 7210.
Sales - Ron
Sales, Profit, Employees, Total Income, Financial Results -
Oncotrials Srl
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Sales - EUR
40.015
33.309
26.495
17.050
7.844
9.925
9.490
21.792
9.840
12.379
Total Income - EUR
40.019
33.371
26.526
17.112
7.846
9.926
9.511
23.183
10.242
12.379
Total Expenses - EUR
21.025
20.825
15.919
18.860
14.239
13.207
7.937
11.509
12.667
12.223
Gross Profit/Loss - EUR
18.994
12.547
10.606
-1.747
-6.393
-3.281
1.575
11.675
-2.425
155
Net Profit/Loss - EUR
17.793
11.879
10.243
-1.918
-6.472
-3.382
1.480
11.443
-2.527
32
Employees
2
2
2
2
1
1
1
1
1
1
The table presents the most important indicators of the company from the Profit and Loss Account for the last 10 years of activity as found at the Ministry of Finance. The data provides the evolution of the company during this period regarding the increases and possibly decreases recorded.
In the last year of activity, the sales increased by 26.5%, from 9.840 euro in the year 2023, to 12.379 euro in 2024.
The Net Profit increased by 32 euro, from 0 euro in 2023, to 32 in the last year.
Check the financial reports for the company - Oncotrials Srl
Financial Rating - ONCOTRIALS SRL
See the company's note based on the submitted financial data, relative to the industry of which it is a part.
Financial Rating
Payment Limits - Oncotrials Srl
See the company's payment capacity for situations in which you conclude contracts with payment terms.
Check Payment Limits
Prob. of insolvency - Oncotrials Srl
It determines the risk of insolvency based on the submitted accounting balance.
Insolvency Probability
Financial Reports - Oncotrials Srl
Check all the financial reports of the company and know the risks in collaboration with it.
Check Financial Reports
Financial Analysis Reports provide a clear and comprehensive view of a company's financial activity. In addition to presenting financial data, the reports analyze this data so that any user can understand whether the results are positive or less favorable. The Financial Rating provides an analysis based on the most important financial ratios, including liquidity, solvency, and profitability. Payment Limits represent the maximum amounts for which a company can offer goods or services on credit to its clients. The Probability of Insolvency presents the theoretical probability that a company may not be able to meet its financial obligations towards its creditors, i.e., suppliers and financial institutions.
The table presents the company's Balance Sheet structure for the last 10 years. Current Assets recorded a value of
7.917 euro in 2024 which includes Inventories of
0 euro, Receivables of
1.876 euro and cash availability of
6.041 euro.
The company's Equity was valued at
8.604 euro, while total Liabilities amounted to
10.536 euro.
Equity increased by 192 euro, from 8.459 euro in 2023, to 8.604 in 2024.
Similar services useful for checking companies and business development.
SellNet
Get the contact details for any company and get in touch with it.
Sectoral Studies
Knows the market and develops its own development strategies according to sectorial data.
Databases
Export in excel files the data of the companies selected according to the desired criteria.
Import - Export
Find importers and exporters according to the type of activity and the countries in which they carry it out.
Similar services represent services associated with companies that allow for a better analysis of clients and suppliers. Company Contacts help you get in touch with the desired companies. Sector Studies provide an overview of an industry, the most important competitors, and the geographical distribution of companies. Company Lists allow you to attract new clients, while Import-Export services give you access to companies engaged in such activities.
Comments - Oncotrials Srl